Novo Nordisk A/S (NYSE: NVO) is rebranding to simply “Novo” as part of a broader cultural and strategic reset driven by CEO Mike Doustdar to sharpen the company’s competitive edge in obesity treatment.
Doustdar has introduced a framework called the “Novo Way,” which emphasizes customer focus, competitiveness, clarity, and care as the company seeks to rebuild its standing in the obesity drug market.
The rebrand reflects a frank internal acknowledgment that Novo has lost meaningful ground to Eli Lilly, which has aggressively expanded its footprint in the U.S. obesity treatment space with Zepbound.
Novo pioneered the modern obesity drug market when it launched Wegovy in the United States in 2021, but Lilly’s more consumer-oriented commercialization approach has since disrupted its early market leadership.
Doustdar has framed the organizational transformation as an effort to make Novo “better and bigger,” signaling that the changes extend well beyond a cosmetic corporate identity refresh.
The competitive battleground has shifted significantly, with Novo now needing to compete more aggressively across distribution, pricing, patient access, and product formats rather than relying on its historical market position.
Novo has moved into oral obesity treatment with a Wegovy pill, a strategically important development given that the company expects oral drugs to represent more than one-third of GLP-1 obesity treatment use by 2030.
The oral market has already become intensely competitive, with Lilly reporting that its Foundayo treatment captured more than 30% of new U.S. oral-treatment patients despite Novo’s Wegovy pill holding roughly 90% of the oral obesity market as of August.
Analysts expect the U.S. obesity treatment market to exceed $100 billion annually by 2030, giving Novo substantial room to recover lost ground if its cultural and commercial reset translates into stronger execution.
The September 21 capital-markets day is expected to give investors a clearer picture of how Doustdar intends to convert the “Novo Way” philosophy into measurable improvements in market share, patient acquisition, and product adoption.
The central challenge for Novo is that a new name and cultural framework only matter if they produce tangible commercial results, particularly as Lilly’s Zepbound continues to pressure Wegovy in the injectable market.
Doustdar’s message to the market is not that Novo has been defeated, but that it must operate with greater urgency and consumer responsiveness to defend and grow one of the most valuable pharmaceutical franchises in the world.
